Frontlight ResearchEarly access
CompletedPhase 2
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)
Key facts
- Who runs it
- Aldeyra Therapeutics, Inc.
- Where
- Bradenton, Dallas, Houston, Richmond, San Antonio, and Tampa, United StatesSee the 6 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 4 people enrolled
- Started
- 4 Nov 2024
- Ended
- 18 Jun 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- ADX-629
- Record updated
- 3 June 2026
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adult ≥ 21 years old on the day of signing the informed consent form
- Clinical diagnosis of alcoholic hepatitis, based on clinical features and laboratory testing, confirmed by the Investigator at screening
- Agreement to abstain from alcohol and utilize resources to cease at-risk behaviors during the trial, including addiction/alcohol abuse treatment
- Ability and willingness to swallow tablets
- Willingness to provide signed informed consent, prior to any trial-related procedures and willingness to comply with the trial procedures and requirements
Who cannot take part
- Current or recent enrollment in another interventional trial in the 30 days prior to screening
- Pregnant, intending to become pregnant (or father a child), or breastfeeding
Where in United States
- Synergry HealthcareBradenton, United States
- The Liver Institute at Methodist Dallas Medical CenterDallas, United States
- UDL Clinical Research, LLCHouston, United States
- Bon Secours Liver Institute of Newport NewsRichmond, United States
- Methodist Specialty and Transplant HospitalSan Antonio, United States
- Florida Health Sciences Center/Tampa General Hospital/USFTampa, United States
About the trial
What the trial wants to find out
A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)
The 2 groups in the trial
- ADX-629 (125 mg twice daily)Treatment being tested
Treatment: ADX-629
- ADX-629 (250 mg twice daily)Treatment being tested
Treatment: ADX-629
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects With Moderate Alcohol Associated Hepatitis
- Record updated
- 3 June 2026